onr:"swepub:oai:lup.lub.lu.se:b6dda1cd-c225-4651-a2c5-4ad74d21d319"
Search: onr:"swepub:oai:lup.lub.lu.se:b6dda1cd-c225-4651-a2c5-4ad74d21d319" > Targeted therapy in...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Oyen, W J G (author)
Targeted therapy in nuclear medicine current status and future prospects
- Article/chapterEnglish2007
Publisher, publication year, extent ...
- Elsevier BV,2007
Numbers
- LIBRIS-ID:oai:lup.lub.lu.se:b6dda1cd-c225-4651-a2c5-4ad74d21d319
- https://lup.lub.lu.se/record/1141293URI
- https://doi.org/10.1093/annonc/mdm111DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Bodei, L (author)
- Giammarile, F (author)
- Maecke, H R (author)
- Tennvall, JanLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Department of Clinical Sciences, Lund(Swepub:lu)onk-jte (author)
- Luster, M (author)
- Brans, B (author)
- TumörmikromiljöSektion I (creator_code:org_t)
Related titles
- In:Annals of Oncology: Elsevier BV18:11, s. 1782-17921569-80410923-7534
Internet link
Find in a library
- Annals of Oncology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Oyen, W J G
- Bodei, L
- Giammarile, F
- Maecke, H R
- Tennvall, Jan
- Luster, M
- show more...
- Brans, B
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Annals of Oncolo ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
